18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy

Arms (1)

1. type

   EXPERIMENTAL

   label

   Diagnostic (PET, pMRI, DTI, IMRT, temozolomide)

   description

   Patients undergo 18F DOPA-PET, pMRI and DTI within 14 days before radiation therapy, 3-6 weeks after radiation therapy, and during follow-up. Patients also undergo IMRT over 30 fractions and receive temozolomide.

   interventionNames

   1. Procedure: Diffusion Weighted Imaging
   2. Drug: Fluorine F 18 Fluorodopa
   3. Radiation: Intensity-Modulated Radiation Therapy
   4. Procedure: Perfusion Magnetic Resonance Imaging
   5. Procedure: Positron Emission Tomography
   6. Other: Quality-of-Life Assessment
   7. Drug: Temozolomide

Primary outcomes (1)

1. measure

   Proportion of Grade IV MGMT Un-methylated Patients That Experience Confirmed-progression-free Survival at 6 Months (CPFS6)

   timeFrame

   Time from registration to the confirmed disease progression, assessed at 6 months

   description

   The proportion of Grade IV MGMT un-methylated patients that experience confirmed-progression-free survival at 6 months (CPFS6). Progression is defined by any of the following: * ≥25% increase in the sum of products of perpendicular diameters of enhancing lesions compared to the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids * Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared to baseline scan or best response following initiation of therapy, not due to co-morbid events * Any new lesion * Clear clinical deterioration not attributable to other causes apart from the tumor or changes in corticosteroid dose. * Failure to return for evaluation due to death or deteriorating condition * Clear progression of non-measurable disease